GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2017
    In:  Age and Ageing Vol. 46, No. Suppl_3 ( 2017-09), p. iii13-iii59
    In: Age and Ageing, Oxford University Press (OUP), Vol. 46, No. Suppl_3 ( 2017-09), p. iii13-iii59
    Type of Medium: Online Resource
    ISSN: 0002-0729 , 1468-2834
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2017
    detail.hit.zdb_id: 2065766-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Elsevier BV ; 2021
    In:  Journal of Geriatric Oncology Vol. 12, No. 6 ( 2021-07), p. 872-880
    In: Journal of Geriatric Oncology, Elsevier BV, Vol. 12, No. 6 ( 2021-07), p. 872-880
    Type of Medium: Online Resource
    ISSN: 1879-4068
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 2556813-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2019
    In:  The Oncologist Vol. 24, No. 9 ( 2019-09-01), p. e968-e977
    In: The Oncologist, Oxford University Press (OUP), Vol. 24, No. 9 ( 2019-09-01), p. e968-e977
    Abstract: Our goal was to determine (a) the prevalence of multimorbidity and polypharmacy in patients with cancer and (b) the prevalence, predictability, and preventability of adverse drug reactions (ADRs) causing/contributing to hospitalization. Materials and Methods We conducted a 12-month prospective observational study of patients aged ≥16 years admitted to an oncology center. Older adults were aged ≥70 years. Results We enrolled 350 patients: 52.3% (n = 183) female, mean age 63.6 years (SD 12.1), 36.6% (n = 121) aged ≥70 years. Multimorbidity (≥2 conditions) was identified in 96.9%; 68% had ≥5 conditions. The median number of medications was 6 (interquartile range [IQR] 4–8); 47% were prescribed ≥6 medications and 11.4% ≥11 medications. Older adults had higher numbers of comorbid conditions (7 [IQR 5–10] vs. 5 [IQR 3–7]) and were prescribed more medications (median 7 [IQR 4–9] vs. 4 [IQR 2–7]). ADRs caused/contributed to hospitalization in 21.5% (n = 75): 35.8% (n = 72) of emergency admissions and 4.7% (n = 3) of elective admissions. The most common ADRs were neutropenia with infection (25.3%), dyspepsia/nausea/vomiting (20%), and constipation (20%). Causative medications included systemic anticancer therapies (SACTs; 53.3%), opioids (17.3%), corticosteroids (6.7%), and nonsteroidal anti-inflammatory drugs (5.3%). ADR prevalence was similar in older and younger adults secondary to SACTs (8.3% vs. 13.1%), non-cancer medications (10.7% vs. 8.3%), and both (0% vs. 1.3%). ADRs were predictable in 89.3% (n = 67), definitely avoidable in 29.3% (n = 22), and possibly avoidable in 33.3% (n = 25). No association was identified between ADRs and age, gender, daily medication number, length of stay, or death. No ADR predictor variables were identified by logistic regression. Conclusion More than 21% of admissions to an oncology service are ADR-related. ADRs are caused by both SACTs and non-cancer-specific medications. The majority are predictable; ≥60% may be preventable. Patients with cancer have high levels of multimorbidity and polypharmacy, which require vigilance for related adverse outcomes. Implications for Practice A diagnosis of cancer often occurs in patients with multimorbidity and polypharmacy. Cancer can cause an altered physiological environment, placing patients at risk of drug-drug interactions, drug-disease interactions, and adverse drug reactions (ADRs). This study identified that ADRs caused or contributed to one in five hospital admissions of patients with cancer. ADRs were caused by systemic anticancer therapies (SACTs) in 53.3% of cases and non-cancer medications in 45.4% of cases, and a combination of both in 1.3%. ADRs occurred in similar frequencies in older and younger patients secondary to SACTs (8.3% vs. 13.1%, p = .295), non-SACTs (10.7% vs. 8.3%, p = .107), and a combination of both (0% vs. 1.3%, p = .240). The majority of ADRs were predictable (89.3%) and potentially preventable (62.6%). These findings support the need for increased awareness of medication-related adversity in patients with cancer and interventions to minimize their occurrence, thus supporting the American Society of Clinical Oncology guidelines that recommend adults ≥65 years of age receiving chemotherapy have geriatric assessment to identify medical and medication issues.
    Type of Medium: Online Resource
    ISSN: 1083-7159 , 1549-490X
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2019
    detail.hit.zdb_id: 2023829-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    Oxford University Press (OUP) ; 2019
    In:  Age and Ageing Vol. 48, No. Supplement_3 ( 2019-09-16), p. iii1-iii16
    In: Age and Ageing, Oxford University Press (OUP), Vol. 48, No. Supplement_3 ( 2019-09-16), p. iii1-iii16
    Abstract: The objectives of this study were to identify the prevalence of severe drug interactions (SDIs) and potentially inappropriate prescriptions (PIPs) in older adults with cancer. Methods A 12-month prospective observational study of patients ≥65 years admitted to an oncology centre was conducted. SDIs were assessed using Stockley’s interaction checker; PIPs were identified using STOPP/START criteria. Logistic regression was applied to determine the influence of age, gender, co-morbidities and medication number on the likelihood of an SDI and a PIP. Results We enrolled 186 participants; mean age 72.5 (SD5.7) years, 46.2% female, mean co-morbidity number 7.5 (SD3.4), median medication number 7 (IQR4-9). Polypharmacy (≥6 medications) and major polypharmacy (≥11 medications) were identified in 60.8% and 17.7% respectively. Systemic anti-cancer therapies (SACTs) were concomitantly prescribed to 60.2%. SDIs were identified in 50.5% participants; 7.5% ≥1 SACT-SACT SDI, 41.4% ≥1 drug-drug SDI and 10.2% ≥1 drug-SACT SDI. The most common SDIs were beta-blocker/alpha-blocker (n=12), Selective serotonin re-uptake inhibitor (SSRI)/proton pump inhibitor (PPI) (n=11) and SSRI/Aspirin (n=8). A strong correlation between medication and SDI number was identified (r2=0.61, p-value 〈 0.001). For each additional prescription, the odds of an SDI increased by 50.8% (Odds ratio 1.508, 95% CI1.288–1.764, p 〈 0.001). PIPs were observed in 73.1%; median 2(IQR1-3). The most common PIPs were drugs prescribed beyond the recommended duration (46.8%), high-dose PPIs 〉 8 weeks (34.9%) and regular opioids without laxatives (20.4%). Patients prescribed ≥1 PIP had more co-morbidities (8.4(SD3.4) vs 5.2(SD2.4), p 〈 0.001), a higher cumulative illness rating score (18(IQR12-20) vs 11(IQR10-14), p 〈 0.001) and more prescribed medications (8(IQR6-10) vs 3(IQR1-4.25), p 〈 0.001). For each additional prescription, the odds of receiving a PIP increased by 79.2% (Odds ratio 1.792, 95% CI1.459–2.02, p 〈 0.001). Conclusion SDIs and PIPs are common in older adults with cancer and higher than previously reported. Comprehensive specialist medication evaluation, by a Geriatrician, may benefit patients.
    Type of Medium: Online Resource
    ISSN: 0002-0729 , 1468-2834
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2019
    detail.hit.zdb_id: 2065766-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 15_suppl ( 2017-05-20), p. e20557-e20557
    Abstract: e20557 Background: Patients with synchronous de novo EGFR sensitising and resistance mutations are rare. Little is known about the response of these patients to EGFR TKIs, especially in a Caucasian population. Methods: We identified NSCLC patients found to have EGFR mutations using PCR-based fragment length analysis, mass spectrometry-based genotyping (Sequenom), and Sanger sequencing using a large multi-institutional database. Baseline clinical characteristics, response rate, progression free survival (PFS) and overall survival (OS) were calculated. Results: From 2008-2015, we observed de novo synchronous EGFR sensitising and resistance mutations in 12 patients representing an overall incidence of 3.6% of EGFR mutants and 0.4% of all NSCLC patients tested. Seven patients were treated using EGFR TKI therapy with erlotinib. In all cases, T790M (n = 4,50%) or S768I (n = 4, 50%) occurred concurrently with another sensitising EGFR mutation, either L858R (n = 4, 34%) or exon 19 deletion (n = 8, 66%). Objective responses were seen in two patients (29%). Three further patients had stable disease lasting 6, 23 and 54 months respectively. The median progression-free survival was 24 months and the median overall survival was 34 months. All patients with baseline EGFR S768I mutations (n = 3) had an objective response or stable disease on erlotinib while two of four patients with T790M demonstrated de novo resistance. Conclusions: This is the largest Irish review of synchronous de novo EGFR mutations. The incidence of co-occurring EGFR mutations was 0.4% and erlotinib demonstrated activity in this cohort of patients. Ongoing trials will determine whether next-generation EGFR TKIs such as osimertinib are preferable as first-line therapy in these patients.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2017
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 189, No. 1 ( 2021-08), p. 269-283
    Type of Medium: Online Resource
    ISSN: 0167-6806 , 1573-7217
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 2004077-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2019
    In:  Irish Journal of Medical Science (1971 -) Vol. 188, No. 2 ( 2019-5), p. 405-408
    In: Irish Journal of Medical Science (1971 -), Springer Science and Business Media LLC, Vol. 188, No. 2 ( 2019-5), p. 405-408
    Type of Medium: Online Resource
    ISSN: 0021-1265 , 1863-4362
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2019
    detail.hit.zdb_id: 2275855-0
    detail.hit.zdb_id: 2468506-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: FEMS Microbiology Letters, Oxford University Press (OUP), Vol. 266, No. 2 ( 2007-01), p. 170-176
    Type of Medium: Online Resource
    ISSN: 0378-1097 , 1574-6968
    URL: Issue
    RVK:
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2007
    detail.hit.zdb_id: 1501716-3
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    SAGE Publications ; 2012
    In:  Journal of Family Issues Vol. 33, No. 1 ( 2012-01), p. 52-75
    In: Journal of Family Issues, SAGE Publications, Vol. 33, No. 1 ( 2012-01), p. 52-75
    Abstract: In this article, the authors explore the consequences of an American 1930s classic anthropological study for a contemporary rural community in the west of Ireland. The contribution of family, kin, and community relations to sustaining a rural way of life was the primary focus of Arensberg and Kimball’s study of Irish farm families published as Family and Community in Ireland. Through the frame of a collaborative community research project with an artist, sociologist, and the descendents of the families written about, we present an account of a research project based on Kimball’s 1930s field diary that provided an opportunity for community members to tell their own story of family and community in the 21st century. Deploying a narrative inquiry approach, the power of local stories to interrupt dominant narratives of family and community is explored.
    Type of Medium: Online Resource
    ISSN: 0192-513X , 1552-5481
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2012
    detail.hit.zdb_id: 1494068-1
    SSG: 3,4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2022
    In:  Journal of Clinical Oncology Vol. 40, No. 16_suppl ( 2022-06-01), p. e24088-e24088
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 16_suppl ( 2022-06-01), p. e24088-e24088
    Abstract: e24088 Background: Up to one third of cancers in high-income populations can be attributed to lifestyle factors (nutrition & physical activity). Data on dietary beliefs in Irish patients with cancer are lacking. This study aims to evaluate how patients with cancer conceptualize the effect of diet on their disease and treatment & determine if attitudes vary according to age, gender, education, disease type, treatment type & treatment intent. Methods: This is a questionnaire-based study, carried out in an Irish oncology unit over a 3-week period in April 2021. Patients with an active cancer diagnosis attending the oncology day ward were invited to participate. We adapted a previously used questionnaire following expert review. A combination of yes/no and Likert scale responses were used: Have you changed your diet since you received your diagnosis? (Yes/no). To what degree do you think that...(Likert): Diet may contribute to the condition that you are being treated for?. Your diet after diagnosis helps your sense of health and wellness?. Diet can help relieve side effects of treatment?. Diet helps in preventing cancer recurrence?. Demographic and treatment data were recorded from patient charts. Responses were compared across demographic variables including gender, age, highest education level, primary cancer location/type and treatment intent using Chi-squared/Fishers exact test. A P-value of 〈 0.05 was considered significant. Results: 130 patients were invited to take part & 113 responded (response rate 87%). 80% reported changing their diet since diagnosis, with no significant difference according to demographic variables. Most (68%) patients expressed a belief that diet played some role in their cancer development although only 15% believed that diet contributed ‘a lot’. Most patients (83%) believed that diet after a cancer diagnosis has an impact on their sense of health and well-being, and 32% expressed a strong belief in this regard (Likert scale 4, ‘a lot’). 75% believed that diet has some impact on managing treatment side effects. 81% believed that diet has some impact on cancer recurrence, and 30% believed it has a major impact (Likert scale 4). On multivariate analysis we found stronger beliefs in the impact of diet on cancer development (p = 0.049) and recurrence risk (p = 0.05) among men than women, and stronger belief in the impact of diet on recurrence risk among patients receiving treatment with curative versus palliative intent (p = 0.045). Conclusions: Most patients reported changing their diet following their cancer diagnosis, and most patients felt that diet had some impact on all of the areas studied including cancer development, health and well-being, managing side effects and cancer recurrence. Men expressed stronger beliefs than women in the impact of diet on cancer development and recurrence risk, and patients being treated with curative intent also expressed stronger beliefs in the impact of diet on cancer recurrence.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...